glp 1 glp 2 GLP-1 receptor agonists are increasingly used to treat type diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Glucagon-like peptide-1: Trends in Endocrinology

Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Multidistrict Litigation 3094 MDL 3094 refers to a multi-district litigation case consolidated in the Eastern District of Pennsylvania Federal Court against drug manufacturers Novo Nordisk (Ozempic, Wegovy, and Rybelsus) and Eli Lilly and Company (Trulicity and Mounjaro)

The dose can be increased to a 1.8 mg/dose for additional glycemic control (Table 1)

Cardiovascular and Kidney Outcomes and Mortality with Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals with Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials